BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201118
DTEND;VALUE=DATE:20201219
DTSTAMP:20260515T140746
CREATED:20200930T094828Z
LAST-MODIFIED:20210118T080755Z
UID:27309-1605657600-1608335999@www.pharmajournalist.com
SUMMARY:CPhI & P-MEC China Virtual Expo Connect
DESCRIPTION:As well as the physical CPhI & P-MEC China 2020 show that will take place in Shanghai from 16th – 18th December\, a digital extension of the event – known as “Virtual Expo Connect” – will take place online from November 18th – December 18th\, allowing you to do business in China\, no matter your location. The hybrid “Virtual Expo Connect” offers an online alternative for international visitors unable to travel to the physical show in China due to travel restrictions\, adding valued services and infinite opportunities to connect\, learn\, trade and grow. \nCPhI & P-MEC China Virtual Expo Connect\nA hybrid offline-2-online platform for global pharma professionals\nNov 18 – Dec 18\, 2020 \nTo know more about CPhI & P-MEC China Virtual Expo Connect please click here.
URL:https://www.pharmajournalist.com/event/cphi-p-mec-china-virtual-expo-connect/
LOCATION:Virtual Event powered by CPhI China & Pharmasources.com
CATEGORIES:e
ORGANIZER;CN="CPhI China & Pharmasources.com":MAILTO:yingqi.shi@imsinoexpo.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201207
DTEND;VALUE=DATE:20201211
DTSTAMP:20260515T140746
CREATED:20200217T121202Z
LAST-MODIFIED:20201123T131643Z
UID:24217-1607299200-1607644799@www.pharmajournalist.com
SUMMARY:BioFIT 2020
DESCRIPTION:Come and join us online for the 9th edition of BioFIT\, from the 7th to the 10th of December 2020! \nWith the highest attending rate of TTOs\, research institutes and academia together with big pharma\, emerging and small biotech\, diagnostics companies\, pre-seed / seed / Series A investors\, BioFIT is the leading partnering event in Europe for technology transfer\, academia-industry collaborations and early-stage innovation deals in the field of Life Sciences. BioFIT is also the European marketplace for pre-seed\, seed and Series A investment in Life Sciences. \n \nKEY FIGURES: \n\n1\,400+ delegates\n900+ organisations\n40+ countries represented\n1\,000 deals generated in 2017\n\nINSIDE THE EVENT: \n\nA business convention with pre-qualified one-to-one meetings\nConferences and roundtable discussions\nOral presentations of start-ups and licensing opportunities stemming from academia\nAn exhibition area\nInformal networking evenings\n\nAcross these 4 days of event\, you will be able to e-meet and network with these attendees from the comfort of your home office. The one-to-one partnering meetings will be possible 24H a day. \nYou will also have access\, for the conferences and the pitch sessions\, to a mix of live and on-demand content during those 4 days and available for 30 days afterwards; and you will also have the opportunity to debate with the speakers and pitchers via interactive online chats. \nWebsite: www.biofit-event.com \nRegistration: www.biofit-event.com/registration-for-biofit/ \nContact: msatola@eurasante.com
URL:https://www.pharmajournalist.com/event/biofit-2020/
LOCATION:Virtual Event
ORGANIZER;CN="Eurasant%C3%A9%2C Clubster NHL%2C BioValley France and Eurobiomed":MAILTO:msatola@eurasante.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201208
DTEND;VALUE=DATE:20201211
DTSTAMP:20260515T140746
CREATED:20200817T090658Z
LAST-MODIFIED:20200817T090658Z
UID:26779-1607385600-1607644799@www.pharmajournalist.com
SUMMARY:2nd Annual Gene Therapy for Neurological Disorders | Running Digitally for 2020
DESCRIPTION:Revolutionize the Development & Delivery of Neurological Gene Therapies  \nReturning this year as a digital meeting with an agenda designed with the field’s thought-leaders including Pfizer\, Biogen\, Voyager and Novartis\, the 2nd Annual Gene Therapy for Neurological Disorders is the industry’s only meeting dedicated to solving your translational drug development challenges\, enabling you to accelerate the development of your neurological gene therapy candidate. \nDon’t get left behind. Attend this meeting to transform gene therapy delivery to the CNS\, optimize translational modelling approaches and discover targeted\, efficacious\, and safe vectors to revolutionize the treatment of neurological disorders. \nTo learn more about Gene Therapy for Neurological Disorders please click here: https://ter.li/c610sy
URL:https://www.pharmajournalist.com/event/2nd-annual-gene-therapy-for-neurological-disorders-running-digitally-for-2020/
LOCATION:Vitual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201208
DTEND;VALUE=DATE:20201211
DTSTAMP:20260515T140746
CREATED:20200819T090705Z
LAST-MODIFIED:20200819T090705Z
UID:26807-1607385600-1607644799@www.pharmajournalist.com
SUMMARY:3rd RNA-Targeted Drug Discovery Summit
DESCRIPTION:The 3rd RNA- Targeted Drug Discovery Summit returns as the most comprehensive and definitive event for the RNA targeting small molecule community to not only address key challenges of the field\, such as successful determination and prediction of RNA structure and role in disease\, but also to drive forward optimized strategies to improve target selection and gain pre-clinical proof of concept to drive the field forward towards translation into clinical development. \n \nWith numerous approaches emerging to demonstrate genuine viability in directly or indirectly targeting RNA with small molecules\, join leading biopharmaceutical directors\, VPs and C-level executives at the 3rd RNA- Targeted Drug Discovery Summit – your premier industry and translational focused conference dedicated to advancing pioneering RNA biology and drug discovery into a blockbuster RNA targeting small molecule therapeutic approach that improves patient outcomes. \nThe world of drug discovery and chemical probes is still protein-centric and developing highly selective small molecules targeting RNA is often considered to be an insurmountable challenge. This view is now changing given the recent progress and scientific breakthroughs in understanding the fundamental biology and function of RNA\, opening the door to RNA targeted small molecule drug discovery. \n  \n  \n\nExplore how to optimize medicinal chemistry insights & RNA biology to enhance robust translation with The Scripps Research Institute\, Anima Biotech & Arrakis Therapeutics\n\n  \n\nSuccessfully target RNA via interfering with RNA-protein interactions/ Epitranscriptomics with insights from Storm Therapeutics\, Accent Therapeutics & Saverna Therapeutics\n\n  \n\nExpand your knowledge of RNA structure\, function & role in disease with insights from Yale University\, H3 Biomedicine & Whitehead Institute for Biomedical Research\n\n  \n\nAdvance identification & validation of viable RNA target sites for therapeutic intervention with insights from PTC Therapeutics & Duke University\n\n  \n\nOvercome binding\, selectivity & drug-like challenges of small molecules targeting RNA with insights from Roche\, University of California San Diego & Novartis\n\n \nTo know more about 3rd RNA-Targeted Drug Discovery Summit please click here.
URL:https://www.pharmajournalist.com/event/3rd-rna-targeted-drug-discovery-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201208
DTEND;VALUE=DATE:20201210
DTSTAMP:20260515T140746
CREATED:20201020T131537Z
LAST-MODIFIED:20201020T131537Z
UID:27562-1607385600-1607558399@www.pharmajournalist.com
SUMMARY:Decentralized Clinical Trails Summit
DESCRIPTION:Strengthen Your Operational and Compliance Protocols to Accelerate Technology-Enabled\, Patient-Centric\, and Cost-Efficient Decentralized Clinical Trials \nWith the potential to improve recruitment rates\, simplify compliance\, reduce drop-out rates\, and speed-up your product’s time to market\, decentralized clinical trials represent an opportunity to rethink and refresh how research studies are conducted\, while keeping the patient at the heart of all trials. \n \nDespite this\, only a fraction of clinical trials are currently run as hybrid of virtual models. This is about to change. The age of decentralized clinical trials is here\, and keeping pace with the rest of the industry means preparing your internal processes for the change. \nCreated in conjunction with clinical trial leaders from big and small pharma\,  forward thinking  academics\, and research institutes\, the programme for this year’s Decentralized Clinical summit has been designed to help you to develop the toolkit you need to run successful decentralised trials. Join over 100+ peers this December to tackle issues such as: using digital tools and wearables\, maintaining data quality and integrity\, simplifying e-consent\, optimising patient recruitment\, restructuring project teams\, rethinking trial design and undertaking study-model matching. \nTo know more about Decentralized Clinical Trails Summit please click here.
URL:https://www.pharmajournalist.com/event/decentralized-clinical-trails-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201208
DTEND;VALUE=DATE:20201211
DTSTAMP:20260515T140746
CREATED:20201026T092432Z
LAST-MODIFIED:20201026T092432Z
UID:27669-1607385600-1607644799@www.pharmajournalist.com
SUMMARY:3rd Microbiome Movement – Skin Health & Dermatology Summit
DESCRIPTION:As the tools and technologies that are available to study the skin microbiome become cheaper and more accessible\, the fundamental mechanisms that link the skin microbiome with skin health are becoming stronger. The demand for skin microbiome products is advancing rapidly which is only being reflected in the increasing number of products on the market that claim to modulate the microbiome. \nDespite this growing opportunity\, there are still a number of basic and clinical science that need addressing to ensure that industry researchers are creating products that demonstrate true impact in patients and consumers. \n \nThe 3rd Microbiome Movement ­– Skin Health & Dermatology Summit returns to unite leaders from academia and industry to address the unique challenges that working within the skin microbiome possesses\, with the goal to accelerate microbiome-targeted therapeutics and cosmetics. \nWith discussions focusing on targeting the microbiome to treat inflammatory skin disease\, exploring how pre\, pro and post biotics can be optimized to improve skin health as well as a view into the regulatory and patent landscape; this opportunity is not to be missed. This is not to mention our new Pre-Conference Commercialization & Marketing Focus Day that will provide a deep dive into consumer education and product differentiation. \nTo know more about 3rd Microbiome Movement – Skin Health & Dermatology Summit please click here.
URL:https://www.pharmajournalist.com/event/3rd-microbiome-movement-skin-health-dermatology-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hansonwade":MAILTO:info@microbiome-movement.com
END:VEVENT
END:VCALENDAR